【摘要】 目的：探究两种不同新辅助化疗方案对乳腺癌患者近期疗效及生存率的影响。方法：选取2016年3月-2017年3月笔者所在医院诊治的乳腺癌患者74例，按新辅助化疗方案的不同分为TE组(37例)和TEC组(37例)。TE组患者采用多西他赛+表柔比星(TE方案)进行化疗，TEC组患者在TE组基础上加用环磷酰胺(TEC方案)进行治疗。比较两组患者近期疗效及2年生存率。结果：TE组治疗总有效率为78.38%，TEC治疗总有效率为81.08%，两组比较差异无统计学意义(P>0.05)。TEC组2年生存率为91.89%，高于TE组的72.97%，差异有统计学意义(P<0.05)。结论：TE方案与TEC方案治疗乳腺癌的临床疗效相当，但TEC方案治疗乳腺癌的2年生存率更高。

    【关键词】 新辅助化疗 乳腺癌 生存 TE TEC

    [Abstract] Objective： To investigate the effect of two different neoadjuvant chemotherapy regimens on the short-term efficacy and survival rate of breast cancer patients. Method： A total of 74 patients with breast cancer diagnosed and treated in our hospital from March 2016 to March 2017 were selected. They were divided into the TE group (n=37) and the TEC group (n=37) according to different neoadjuvant chemotherapy regimens. The TE group received Docetaxel and Epirubicin (TE regimen) for chemotherapy ......